Naurex presents 'compelling' data for depression drug GLYX-13

Arizona's Naurex has presented detailed results from its Phase IIb trial of depression drug GLYX-13, which show that the product had a fast and significant effect in reducing depression symptoms, which was sustained over six weeks. The company confirmed that it will be going ahead with its planned Phase III trial at the beginning of 2015.

In a study of 386 patients, presented at the annual meeting of American College of Neuropsychopharmacology, GLYX-13's efficacy increased over...